Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6666962 | 0.79 | ALDH1A1 (0.39) | ALDH1A1IMPDH2HDAC1HDAC6CA12 | |
| SCHEMBL2647990 | 0.79 | ALDH1A1 (0.39) | ALDH1A1HDAC1HDAC6CA12CA1 | |
| SCHEMBL313506 | 0.77 | CES2 (0.36) | CES2CES1 | |
| SCHEMBL23899705 | 0.75 | ALDH1A1 (0.36) | ALDH1A1IMPDH2HDAC1HDAC6CA6 | |
| SCHEMBL18152933 | 0.75 | TSHR (0.36) | ALDH1A1IMPDH2CA12CA1CA2 | |
| SCHEMBL31152966 | 0.75 | CYP3A4 (0.36) | ALDH1A1IMPDH2HDAC1HDAC6 | |
| SCHEMBL112835 | 0.75 | ALDH1A1 (0.43) | ALDH1A1HDAC1HDAC6CA12CA1 | |
| SCHEMBL15231722 | 0.74 | ALDH1A1 (0.39) | ALDH1A1HDAC1HDAC6CA12CA1 | |
| SCHEMBL22366550 | 0.73 | IMPDH2 (0.42) | ALDH1A1IMPDH2CA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL3032172 | 0.72 | ALDH1A1 (0.42) | ALDH1A1HDAC1HDAC6CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688748-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| WO-2025264645-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2014023674-A1 | PIPERAZINO[1,2-A]INDOL-1-ONES AND [1,4]DIAZEPINO[1,2-A]INDOL-1-ONE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-13 | — | — | WO | disclosed |
| WO-2013093484-A1 | PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-27 | — | — | WO | disclosed |
| EP-1735293-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087752-A2 | SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-6716352-B1 | TRANSFERRING ACIDIC STRIPPING SOLUTION ACROSS SELECTIVELY PERMEABLE MEMBRANE | MEMBRANE EXTRACTION TECHNOLOGY LIMITED (GB) | 2004-04-06 | — | — | US | disclosed |
| EP-1210297-A1 | METHOD FOR REMOVING AND RECOVERING AROMATIC AMINES BY USING A NON-POROUS MEMBRANE | Membrane extraction Technology Ltd. (GB) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001009042-A1 | METHOD FOR REMOVING AND RECOVERING AROMATIC AMINES BY USING A NON-POROUS MEMBRANE | MEMBRANE EXTRACTION TECHNOLOGY LIMITED (GB) | 2001-02-08 | — | — | WO | disclosed |
| CN-1037147-A | N-cyclopropyl aniline and the application in preparation 1-cyclopropyl quinolone carboxylic acid and its derivative thereof | BAYER AG (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0332033-A2 | N-cyclopropyl anilines and their use in processes for the synthesis of 1-cyclopropyl-quinolone-carboxylic acids and their derivatives | BAYER AG (DE) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239790-A1 | Substituted hydroxyethylamine aspartyl protease inhibitors | DNPEP, MME, ANPEP | ALDH1A1 1971/4885IMPDH2 3162/4885HDAC1 2603/4885 |
| US-12448369-B2 | Quinolinone amide compounds and uses thereof | TNNI3, TNNT2, COQ8A | ALDH1A1 461/4885IMPDH2 2091/4885HDAC1 151/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | ALDH1A1 2933/4885IMPDH2 3783/4885HDAC1 282/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | ALDH1A1 716/4885IMPDH2 2989/4885HDAC1 213/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | ALDH1A1 1503/4885IMPDH2 4344/4885HDAC1 1202/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | ALDH1A1 780/4885IMPDH2 1083/4885HDAC1 365/4885 |
| US-20260008774-A1 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | TNNT2, TNNI3, TNNC1 | ALDH1A1 1031/4885IMPDH2 3907/4885HDAC1 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.